New York, June 7, 2022: Insilico Medicine’s end-to-end AI-based drug discovery platform, Pharma.AI, derives its strength from the quality and quantity of its data. As a member of the Scientific Council of Insilico and winner of the Nobel Prize in Chemistry Dr. Michael Levitt saidInsilico’s platform capitalizes on the ability of artificial intelligence to extract large amounts of data from many different compounds, find patterns and make predictions that can pave the way for life-saving new drugs.

Insilico started building its platform, using massive data collection, from 2014 when the company was founded. PandaOmics™, the target discovery part of Pharma.AI, uses 1.9 trillion data points drawn from over 10 million samples (such as microarrays, RNA sequencing and proteomes) and more than 40 million documents (including patents, grants, publications and clinical trial reports). Insilico tracks federal grant money from initial experiments to clinical trials, manually entering as needed, including trillions in total. PandaOmics can now not only identify brand new targets for drugs, but it can also predict which targets are likely to be “hot” five years from now.

Improving AI with CROs and Pharma Partners

One of the ways Insilico enhances its platform with data is by engaging more than 80 contract research organizations that conduct redundant experiments and create reproducible datasets. The company has 30 in-house therapeutic programs in various stages of development and is producing preclinical candidates at a record pace. It has named 8 preclinical candidates since 2021, including one for COVID-19 and two for cancer in recent months, and its leading candidate for idiopathic pulmonary fibrosis is currently in phase 1 trialsthe first drug discovered and designed by AI to achieve this milestone.

Insilico has also expanded its collaborations with the pharmaceutical industry through co-development and software licensing agreements. Since the launch of PandaOmics™ and Chemistry42™ in late 2020, nine of the top 20 pharmaceutical companies, measured by 2020 revenue, have licensed Insilico’s AI platforms. In 2022, Insilico signed multi-asset partnerships with Fosun Pharma and EQRX in January and March, respectively. Insilico notably reached its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy less than 40 days in strategic collaboration with Fosun Pharma.

Next step: robots

Now, Insilico aims to further strengthen its end-to-end AI platform by launching its own AI-driven robotics lab. The lab has been in the design phase for two years and is expected to be fully operational this year. It is a real-world, interconnected extension of Insilico’s drug discovery platform and will be autonomously managed by its AI system with autonomous guided vehicles running experiments instead of scientists. humans. These robots will do cell culture, high-throughput screening, next-generation sequencing, cell imaging, and genomic analysis and prediction. As the robots generate data, that data will feed directly into the PandaOmics platform, improving the system’s target hypotheses and its ability to validate those hypotheses.

“These robots are faster and more accurate than humans,” says Founder and CEO of Insilico Medicine Alex Zhavoronokov, PhD. “And as they perform experiments, they feed the AI ​​system with data, improving the system’s target hypotheses and its ability to validate those hypotheses.”

This is all part of the company’s drive to improve and validate its platform, bring its lead candidate to phase 2 trials, and further develop its many therapeutic programs. Recently, the company received additional funding as part of a $60 Million Series D Round from leading biotech investors including BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital.

Feng Ren, PhD, Scientific Director of Insilico and Head of Global Research and Development who has 15 years of experience in large pharmaceutical and CRO companies says, “We plan to continue to expand the pipeline and improve our AI and robotics capabilities globally. Our rapidly growing team is comprised of talented and experienced drug discovery scientists with diverse backgrounds and an unrelenting passion for novelty and innovation, and fully committed to new drug development with a sense of emergency for waiting patients.

A LOOK INSIDE THE NEW AI ROBOTICS LAB (VIDEO)

About Insilico Medicine

Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system diseases and diseases related to aging.

For more information, visit www.insilico.com

For media inquiries, please contact [email protected]

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.